Knight Therapeutics Inc. (TSX:GUD)

Market Cap	572.85M
Revenue (ttm)	372.78M
Net Income (ttm)	11.06M
Shares Out	99.63M
EPS (ttm)	0.10
PE Ratio	57.56
Forward PE	79.86
Dividend	n/a
Ex-Dividend Date	n/a

Volume	19,861
Average Volume	89,018
Open	5.75
Previous Close	5.75
Day's Range	5.75 - 5.87
52-Week Range	5.09 - 6.45
Beta	0.15
RSI	44.36
Earnings Date	Aug 7, 2025

About Knight Therapeutics

Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Employees: 745
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: GUD